叠氮胸苷临床代谢物抑制实验性脉络膜新生血管和视网膜色素上皮变性
研究评估叠氮胸苷(AZT)的无抗逆转录病毒活性肝脏临床代谢物5『-葡萄糖醛酸叠氮胸苷(GAZT)在小鼠视网膜色素上皮(RPE)变性和脉络膜新生血管(CNV)模型中的疗效。GAZT抑制Alu RNA诱导的RPE变性和激光诱导的CNV,并减少Alu RNA诱导的caspase-1活化和IL-1β释放。GAZT具有双重抗炎和抗血管生成特性,可能成为干性和湿性年龄相关性黄斑变性(AMD)的可行治疗选择。
要点
- GAZT抑制Alu RNA诱导的小鼠RPE变性。
- GAZT抑制激光诱导的小鼠CNV。
- GAZT减少Alu RNA诱导的caspase-1活化和IL-1β释放。
核心结论
- GAZT具有双重抗炎和抗血管生成特性,可能成为干性和湿性AMD的可行治疗选择。
研究设计与样本
- 在野生型C57BL/6J小鼠中,通过视网膜下注射Alu RNA诱导RPE变性,通过激光损伤诱导CNV。
- AZT和GAZT通过玻璃体腔注射给药。
- 在Alu RNA处理的骨髓来源巨噬细胞(BMDMs)中,通过western blot检测caspase-1和ELISA检测IL-1β来监测炎症小体活化。
主要发现
- GAZT抑制Alu RNA诱导的RPE变性和激光诱导的CNV。
- GAZT减少Alu RNA诱导的BMDMs中caspase-1活化和IL-1β释放。
临床怎么用
- GAZT可能作为干性和湿性AMD的潜在治疗药物,但尚未在人体中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Azidothymidine (AZT), a nucleoside reverse transcriptase inhibitor, possesses anti-inflammatory and anti-angiogenic activity independent of its ability to inhibit reverse transcriptase. The aim of this study was to evaluate the efficacy of 5'-glucuronyl azidothymidine (GAZT), an antiretrovirally inert hepatic clinical metabolite of AZT, in mouse models of retinal pigment epithelium (RPE) degeneration and choroidal neovascularization (CNV), hallmark features of dry and wet age-related macular degeneration (AMD), respectively. METHODS: RPE degeneration was induced in wild-type (WT) C57BL/6J mice by subretinal injection of Alu RNA. RPE degeneration was assessed by fundus photography and confocal microscopy of zonula occludens-1-stained RPE flat mounts. Choroidal neovascularization was induced by laser injury in WT mice, and CNV volume was measured by confocal microscopy. AZT and GAZT were delivered by intravitreous injections. Inflammasome activation was monitored by western blotting for caspase-1 and by ELISA for IL-1β in Alu RNA-treated bone marrow-derived macrophages (BMDMs). RESULTS: GAZT inhibited Alu RNA-induced RPE degeneration and laser-induced CNV. GAZT also reduced Alu RNA-induced caspase-1 activation and IL-1β release in BMDMs. CONCLUSIONS: GAZT possesses dual anti-inflammatory and anti-angiogenic properties and could be a viable treatment option for both forms of AMD.
引用
- Narendran S, Pereira F, Yerramothu P, et al. A Clinical Metabolite of Azidothymidine Inhibits Experimental Choroidal Neovascularization and Retinal Pigmented Epithelium Degeneration. Invest Ophthalmol Vis Sci. 2020. PMID: 32749462. doi:10.1167/iovs.61.10.4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。